Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers

NCT02526316 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

HPV-induced Cancers

Interventions

BIOLOGICAL: P16_37-63 peptide combined with Montanide® ISA-51 VG
BIOLOGICAL: P16_37-63 peptide without Montanide® ISA-51 VG

Sponsor

Oryx GmbH & Co. KG